Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 19

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 19
---
 the market price of our Common Stock.

<div align='center'>5</div>

Certain existing securityholders purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in us may not experience a similar rate of return.

Certain of our securityholders, including the Selling Stockholders,
acquired our securities at prices below the current trading prices of our Common Stock and may experience a positive rate of return. In the case of the Selling Stockholders, such potential positive rate of return ranges
from $0 to $5.604 based on the current trading prices. Such stockholders may realize a positive rate of return on the sale of their shares
of Common Stock covered by this prospectus even if the market price per share of our Common Stock is below $15.60 per share. On August
7, 2025, the closing price of our Common Stock as reported on the Nasdaq was $8.10 per share. While some of the Selling Stockholders may
experience a positive rate of return based on the current trading price, public securityholders may not experience a similar rate of return
on the securities they purchased due to differences in the purchase prices they paid and the trading price at the time of sale and may
instead experience a negative rate of return on their investment.

See the section titled “Information Related to Offered Securities” for more information.

In addition to any resales pursuant to such registration
statements, subject to applicable transfer restrictions and the conditions to the availability of Rule 144 for former shell companies
under Rule 144(i), shares of Common Stock held by these stockholders will be eligible for resale, potentially subject to, in the case
of stockholders who are our affiliates, volume, manner of sale, and other limitations under Rule 144 promulgated under the Securities
Act.

In addition, shares of our Common Stock issuable
upon exercise or vesting of incentive awards under our incentive plans are, once issued, eligible for sale in the public market, subject
to any lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144. Furthermore,
shares of our Common Stock reserved for future issuance under our incentive plan may become available for sale in future.

The market price of shares of our Common Stock
could drop significantly if the holders of the shares of Common Stock described above sell them or are perceived by the market as intending
to sell them.